• Fenton Markevich – President and Chief Executive Officer

    Fenton has served as President and Chief Executive Officer of RxStrategies, Inc since 2005. With more than 30 years of experience as a Chief Financial Officer and Chief Executive Officer of technology based organizations, Markevich brings a disciplined approach to addressing the complex issues of managing and administering the complexities of the 340B program.

  • David Wanless – Vice President of Technical Operations and Development

    David joined RxStrategies more than 10 years ago with an extensive knowledge of sales, operations, pharmaceuticals and technology. Throughout his 10-year tenure with RxStrategies, Wanless has focused on design, development and management for the following projects: 340B inventory processing and management system, Prescription Benefit Manager (PBM) and Customer Relationship Manager (CRM). As Vice President of Technical Operations and Development, Wanless oversees technical operations and system development. Previously, Wanless served as Senior Business Analyst for ABB Optical where he played a key role in growing the company into the largest optical distributor in the US.

    Wanless holds a Bachelors of Arts in Biology from Boston University.

  • Skip Devanny – Chief Revenue Officer

    Skip Devanny, Chief Revenue Officer, oversees RxStrategies sales and marketing including the delivery of customized 340B pharmacy administration and split billing solutions to the growing 340B marketplace.  Devanny joined RxStrategies in 2015 with an extensive background in 340B leadership, split billing and contract pharmacy market facing roles. He works closely with RxStrategies’ senior leadership team to design and deliver innovative 340B solutions to the market and its clients.

    Devanny holds a Masters in Business Administration from Washington University and Bachelors Degree from Trinity University.